Date: 2013-07-08
Type of information: Licensing agreement
Compound: Locked Nucleic Acid (LNA) technology
Company: Santaris Pharma (Denmark) RaNA Therapeutics (USA)
Therapeutic area: undisclosed
Type agreement: licensing
Action mechanism:
Disease: undisclosed
Details: * On July 8, 2013, Santaris Pharma and RaNA Therapeutics have announced that they have signed an agreement whereby RaNA gains access to Santaris’ Locked Nucleic Acid (LNA) technology to develop RNA-targeted medicines. Under the terms of the agreement, Santaris will license its proprietary Locked Nucleic Acid drug technology to RaNA for the development of LNA-based drug candidates against up to 10 RaNA proprietary RNA targets. The license granted by Santaris includes access to proprietary chemistry capable of delivering potent single-stranded LNA-based drug compounds. RaNA will apply the LNA chemistry along with its proprietary technologies for selective protein activation to develop RNA-targeted medicines.
Financial terms: Santaris will receive an upfront payment and is eligible for target nomination payments, development milestones and royalties on each product.
Latest news:
